CFC
VRTX icon

Coyle Financial Counsel’s Vertex Pharmaceuticals VRTX Stock Holding History

Coyle Financial Counsel’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-17
Closed -$3K – 296
2018
Q2 		$3K Buy
+17
New +$2.63K ﹤0.01% 263

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Coyle Financial Counsel's VRTX Position: Q3 2018 in Review

Coyle Financial Counsel sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 17 shares — an estimated $3K sold.

Coyle Financial Counsel first reported a position in VRTX in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 696 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

  • Coyle Financial Counsel reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Coyle Financial Counsel sold 17 Vertex Pharmaceuticals shares in Q3 2018, an estimated $3K.
  • Coyle Financial Counsel first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Coyle Financial Counsel's Vertex Pharmaceuticals position peaked at $3K in Q2 2018.
  • 696 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Coyle Financial Counsel's 13F filing for Q3 2018, filed 13 Nov 2018.